Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC |
WINGER DENNIS LDirector
|
Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · derivative · entry 5 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC |
WINGER DENNIS LDirector
|
Exercise / conversionStock Option · Derivative | 18,750 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · derivative · entry 4 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 18,750 shares Expires 2019-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments over four years. Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC |
WINGER DENNIS LDirector
|
Disposition to issuerCommon Stock | 38,750 | $41.65 | $1,613,937.50 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · nonDerivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · price: Open market sales reported on this line occurred at a weighted average price of $41.65 (range $41.61 to $41.74). F2 · price: Mr. Winger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC |
WINGER DENNIS LDirector
|
GrantCommon Stock | 20,000 | $34.24 | $684,800.00 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · nonDerivative · entry 2 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,250 Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC |
WINGER DENNIS LDirector
|
GrantCommon Stock | 18,750 | $34.05 | $638,437.50 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,250 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 17:40 UTC |
Silva Paul MSVP & Corp Controller
|
SaleCommon Stock | 6,875 | $39.36 | $270,600.00 |
DisclosureSEC source: 0001209191-12-014869 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,125 F1 · price: Open market sales reported on this line occurred at a weighted average price of $39.36 (range $39.34 to $39.39). F2 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2012 Filed Feb 29, 2012 17:55 UTC |
BOGER JOSHUA SDirector
|
GiftCommon Stock | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-013857 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,449 F1 · shares: Common stock given to family members. Read SEC document |
| February 08, 2012 Filed Feb 9, 2012 21:09 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 8,133 | $36.80 | $299,294.40 |
DisclosureSEC source: 0001209191-12-008686 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,575 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.80 (range $36.50 to $37.25). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2012 Filed Feb 9, 2012 21:09 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 4,066 | $36.81 | $149,669.46 |
DisclosureSEC source: 0001209191-12-008688 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,108 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.81 (range $36.51 to $37.20). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2012 Filed Feb 9, 2012 21:10 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 9,667 | $36.80 | $355,745.60 |
DisclosureSEC source: 0001209191-12-008690 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,168 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.80 (range $36.48 to $37.20). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:04 UTC |
Emmens MatthewExecutive Chairman
|
GrantStock Option · Derivative | 236,000 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007770 · doc4.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,000 Underlying: Common Stock · 236,000 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:04 UTC |
Emmens MatthewExecutive Chairman
|
GrantCommon Stock | 47,201 | $0.01 | $472.01 |
DisclosureSEC source: 0001209191-12-007770 · doc4.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,601 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:05 UTC |
Howton David TSVP & Chief Legal Officer
|
GrantStock Option · Derivative | 68,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007772 · doc4.xml · derivative · entry 3 Howton David T · CIK 0001529297 · SVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 Underlying: Common Stock · 68,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:05 UTC |
Howton David TSVP & Chief Legal Officer
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007772 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,437 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:06 UTC |
Kelly LisaSVP, Human Resources
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007774 · doc4.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:06 UTC |
Kelly LisaSVP, Human Resources
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007774 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,708 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:07 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
GrantStock Option · Derivative | 72,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007775 · doc4.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:07 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
GrantCommon Stock | 14,501 | $0.01 | $145.01 |
DisclosureSEC source: 0001209191-12-007775 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,236 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:11 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007777 · doc4.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:11 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007777 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,174 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:13 UTC |
Silva Paul MSVP & Corp Controller
|
GrantStock Option · Derivative | 18,000 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007781 · doc4.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:13 UTC |
Silva Paul MSVP & Corp Controller
|
GrantCommon Stock | 4,500 | $0.01 | $45.00 |
DisclosureSEC source: 0001209191-12-007781 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:14 UTC |
SMITH IAN FEVP & CFO
|
GrantStock Option · Derivative | 54,375 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007782 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:14 UTC |
SMITH IAN FEVP & CFO
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0001209191-12-007782 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,835 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC |
Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007783 · doc4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC |
Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007783 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · SVP, Corp Strategy & Bus Devlp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,708 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC |
Wysenski NancyEVP, Chief Commercial Officer
|
GrantStock Option · Derivative | 72,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007784 · doc4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC |
Wysenski NancyEVP, Chief Commercial Officer
|
GrantCommon Stock | 14,501 | $0.01 | $145.01 |
DisclosureSEC source: 0001209191-12-007784 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,394 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| January 19, 2012 Filed Jan 23, 2012 21:36 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 10,166 | $37.00 | $376,142.00 |
DisclosureSEC source: 0001209191-12-004850 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,542 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.84 to $37.15). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 19, 2012 Filed Jan 23, 2012 21:37 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
SaleCommon Stock | 4,066 | $37.00 | $150,442.00 |
DisclosureSEC source: 0001209191-12-004852 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,008 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.84 to $37.10). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 19, 2012 Filed Jan 23, 2012 21:37 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 6,042 | $37.00 | $223,554.00 |
DisclosureSEC source: 0001209191-12-004855 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,751 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.85 to $37.11). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 19, 2012 Filed Jan 23, 2012 21:38 UTC |
Wysenski NancyEVP, Chief Commercial Officer
|
SaleCommon Stock | 6,042 | $37.00 | $223,554.00 |
DisclosureSEC source: 0001209191-12-004858 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,893 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.85 to $37.10). F3 · price: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 21:29 UTC |
LEIDEN JEFFREY MDirector · CEO Designate
|
GrantStock Option · Derivative | 458,108 | $0.00 Strike: $29.99 | $0.00 |
DisclosureSEC source: 0001209191-11-061776 · doc4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO Designate 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,108 Underlying: Common Stock · 458,108 shares Expires 2021-12-13 F3 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 12/14/2011. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 21:29 UTC |
LEIDEN JEFFREY MDirector · CEO Designate
|
GrantCommon Stock | 133,378 | $0.01 | $1,333.78 |
DisclosureSEC source: 0001209191-11-061776 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO Designate 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,995 F2 · shares: Performance-based stock grant under 2006 Stock and Option Plan that will vest only if Vertex meets certain performance objectives. Up to 50% of the grant will vest on the date of the Company's first regularly scheduled board meeting in 2013 and up to 50% of the grant will vest on the date of the Company's 2014 Annual Meeting of its shareholders. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 21:29 UTC |
LEIDEN JEFFREY MDirector · CEO Designate
|
GrantCommon Stock | 50,017 | $0.01 | $500.17 |
DisclosureSEC source: 0001209191-11-061776 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO Designate 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,617 F1 · shares: Stock grant under 2006 Stock and Option Plan vesting on December 14, 2014. Read SEC document |
| December 12, 2011 Filed Dec 13, 2011 22:22 UTC |
Wysenski NancyEVP, Chief Commercial Officer
|
SaleCommon Stock | 5,000 | $28.90 | $144,500.00 |
DisclosureSEC source: 0001209191-11-061087 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,935 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $28.90 (range $28.75 to $29.17). F3 · price: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2011 Filed Feb 13, 2015 21:17 UTC |
MCGLYNN MARGARET GDirector
|
PurchaseCommon Stock | 9 | $29.19 | $262.71 |
DisclosureSEC source: 0001209191-15-013522 · doc5.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · balance_after: As of 12/31/2014. Read SEC document |
| December 06, 2011 Filed Dec 7, 2011 20:38 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option · Derivative | 4,054 | $0.00 Strike: $24.66 | $0.00 |
DisclosureSEC source: 0001209191-11-059998 · doc4.xml · derivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,054 shares Expires 2011-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 06, 2011 Filed Dec 7, 2011 20:38 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,054 | $24.66 | $99,971.64 |
DisclosureSEC source: 0001209191-11-059998 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2011 Filed Feb 13, 2015 21:17 UTC |
MCGLYNN MARGARET GDirector
|
PurchaseCommon Stock | 33 | $29.66 | $978.78 |
DisclosureSEC source: 0001209191-15-013522 · doc5.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · balance_after: As of 12/31/2014. Read SEC document |
| December 01, 2011 Filed Dec 2, 2011 19:48 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option · Derivative | 4,946 | $0.00 Strike: $24.66 | $0.00 |
DisclosureSEC source: 0001209191-11-059066 · doc4.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2011-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| December 01, 2011 Filed Dec 2, 2011 19:48 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,946 | $29.23 | $144,571.58 |
DisclosureSEC source: 0001209191-11-059066 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,395 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $29.23 (range $28.85 to $29.44). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 01, 2011 Filed Dec 2, 2011 19:48 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,946 | $24.66 | $121,968.36 |
DisclosureSEC source: 0001209191-11-059066 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2011 Filed Nov 28, 2011 18:59 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option · Derivative | 4,000 | $0.00 Strike: $24.66 | $0.00 |
DisclosureSEC source: 0001209191-11-058134 · doc4.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,946 Underlying: Common Stock · 4,000 shares Expires 2011-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 23, 2011 Filed Nov 28, 2011 18:59 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,000 | $27.17 | $108,680.00 |
DisclosureSEC source: 0001209191-11-058134 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,395 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $27.17 (range $27.03 to $27.76). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 23, 2011 Filed Nov 28, 2011 18:59 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,000 | $24.66 | $98,640.00 |
DisclosureSEC source: 0001209191-11-058134 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2011 Filed Feb 13, 2015 21:17 UTC |
MCGLYNN MARGARET GDirector
|
PurchaseCommon Stock | 31 | $28.00 | $868.00 |
DisclosureSEC source: 0001209191-15-013522 · doc5.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · balance_after: As of 12/31/2014. Read SEC document |
| November 16, 2011 Filed Nov 17, 2011 18:57 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionStock Option · Derivative | 4,000 | $0.00 Strike: $24.66 | $0.00 |
DisclosureSEC source: 0001209191-11-056675 · doc4.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,946 Underlying: Common Stock · 4,000 shares Expires 2011-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 16, 2011 Filed Nov 17, 2011 18:57 UTC |
BOGER JOSHUA SDirector
|
SaleCommon Stock | 4,000 | $29.71 | $118,840.00 |
DisclosureSEC source: 0001209191-11-056675 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,395 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $29.71 (range $29.27 to $29.95). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2011 Filed Nov 17, 2011 18:57 UTC |
BOGER JOSHUA SDirector
|
Exercise / conversionCommon Stock | 4,000 | $24.66 | $98,640.00 |
DisclosureSEC source: 0001209191-11-056675 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.